Recently, several trials have demonstrated potential benefit of immune checkpoint inhibitors in high grade ER+/HER2− breast cancer.9,10 Given the ability to target the tumor immune microenvironment (TIME) and the potential benefits of immune therapy in combination with adjuvant chemotherapy, there is a need to better understand TIME across breast cancer subtypes.5,11. This evidence concerns the gene ESR1 and breast cancer.